Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

To join this study, you generally need to be at least 18 years old and have non-small cell lung cancer with specific genetic changes (EGFR mutation and changes in a gene called MET) that cannot be cured by surgery or radiation. Your cancer must have sadly gotten worse after being treated with osimertinib recently. Doctors will also need to be able to measure your cancer on scans and you should be generally well enough to take part, as assessed by your doctor.

There are also some reasons why you might not be able to join. For instance, if you have a different type of lung cancer, or if you've already had certain other treatments (like savolitinib or other similar drugs) or other specific types of osimertinib. You also can't have certain serious heart problems, brain or spinal problems that aren't stable, or unstable infections like HIV. Your doctor will carefully check all these points to make sure the study is right and safe for you.

If you join this study, you will be randomly assigned to one of two groups: either receiving the new combination of savolitinib and osimertinib, or receiving standard chemotherapy (like Pemetrexed with Cisplatin or Carboplatin). You won't get to choose which group you're in, as this helps ensure fair comparisons.

You'll take your study medicine or receive chemotherapy according to a schedule decided by the research team. This will involve regular visits to the clinic for medical check-ups, blood tests, and scans to see how the treatment is working and monitor for any side effects. You will continue treatment for as long as it is helping to control your cancer and you are tolerating it well. The total time you spend on the study will depend on how you respond to the treatment, but you will be monitored closely throughout.